Dual HER2 blockade: preclinical and clinical data

Breast Cancer Research

Table 4 Pathologic complete response with dual HER2 regimen in hormone receptor-negative versus hormone receptor-positive subsets of HER2 positive breast cancer: an exploratory comparison

Study	pCR breast and lymph node combination T + L or T + P (%)	pCR breast and lymph node combination T + L or T + P ER-negative subset (%)	pCR breast and lymph node combination T + L or T + P ER-positive subset (%)
NeoALTTO [12],[34]	46.8	61.3	41.6
CHER-LOB [35]	46.7	41.3	28.8
NSABP 41 [36]	60.2	55.6	73
CALGB 40601 [37]	52	66	42
TRIO US B07 [38]	52	67	40
NeoSphere [19],[32]	39.3	63.2	26
TRYPHAENA [43]	50.7 FECPH → DPH	79.4	46.2
	51.9 TCHP	83.8	50
LPT 109096 [39]	74	NR	NR

DPH, docetaxel, pertuzumab and trastuzumab; ER, estrogen receptor; FECPH, fluorouracil, epirubicin, cyclophosphamide, pertuzumab and trastuzumab; HER, human epidermal growth factor receptor; L, lapatinib; NR, not reported; P, pertuzumab; pCR, pathologic complete response; T, trastuzumab; TCHP, docetaxel, carboplatin, trastuzumab and pertuzumab.

ISSN: 1465-542X